

1 **Long-term individual and population functional outcomes in older adults with atrial**
2 **fibrillation**

3
4 Anna L. Parks, MD (1), Sun Y. Jeon, MS PhD (2), W. John Boscardin, PhD (2, 4), Michael A.
5 Steinman, MD (2), Alexander K. Smith, MD, MPH, MAS (2), Margaret C. Fang, MD, MPH (3),
6 Sachin J. Shah, MD, MPH (3)

7
8 (1) Division of Hematology and Oncology, University of California, San Francisco, San
9 Francisco, CA

10 (2) Division of Geriatrics, University of California, San Francisco and San Francisco VA
11 Medical Center, San Francisco, CA

12 (3) Division of Hospital Medicine, University of California, San Francisco, San Francisco, CA

13 (4) Department of Epidemiology and Biostatistics, University of California, San Francisco,
14 San Francisco, CA

15
16
17 Corresponding Author

18 Anna Parks, MD

19 Division of Hematology

20 University of California, San Francisco,

21 505 Parnassus Ave., San Francisco, CA 94143

22 E-mail: Anna.Parks@ucsf.edu;

23 Phone: (801) 209-3969;

24 Fax: (415) 514-2094

25
26
27 **Running title:** Parks - Stroke and Long-term function in AF

28
29 **Main text word count:** 2977

30 **Abstract word count:** 296/300

31
32 **Impact statement:** We certify that this work is novel. Little is known about long-term function
33 (ADL, IADL, community-dwelling) among older adults with AF and the association with stroke.

34 This nationally representative study finds a high rate of function loss independent of stroke, and
35 among those who suffer a stroke, a dramatic and immediate decline in function. Because of the

36 high rate of function loss independent of stroke and the relatively low rate of stroke, on a

37 population level, stroke is not the dominant determinant of disability in older adults with AF.

38

39 **Abstract (297/300)**

40 **Background:** Older adults with atrial fibrillation (AF) have multiple risk factors for disablement.
41 Long-term function and the contribution of strokes to disability has not been previously
42 characterized.

43 **Methods:** We performed a longitudinal, observational study in the nationally representative
44 Health and Retirement Study (1992-2014). We included participants ≥ 65 years with Medicare
45 claims who met incident AF diagnosis claims criteria. We examined the association of incident
46 stroke with three functional outcomes: independence with activities of daily living (ADL) and
47 instrumental activities of daily living (IADL) and community-dwelling. We fit separate logistic
48 regression models with repeated measures adjusting for comorbidities and demographics to
49 estimate the effect of stroke on function. We estimate the contribution of strokes to the overall
50 population burden of functional impairment using the method of recycled predictions.

51 **Results:** Among 3530 participants (median age 79 years, 53% women, median CHA₂DS₂-VASc
52 5), 262 had a stroke over 17,396 person-years. Independent of stroke and accounting for
53 population comorbidities, annually, ADL dependence increased by 4.4%, IADL dependence
54 increased by 3.9%, and nursing home residence increased by 1.2% ($p < 0.05$ for all). Accounting
55 for comorbidities, of those who experienced a stroke, 31.9% developed new ADL dependence,
56 26.5% developed new IADL dependence, and 8.6% newly moved to a nursing home ($p < 0.05$ for
57 all). Considering all causes of function loss, 1.7% of ADL disability-years, 1.2% of IADL
58 disability-years, and 7.3% of nursing home years could be attributed to stroke over 7.4 years.

59 **Conclusion:** Older adults lose substantial function over time following AF diagnosis,
60 independent of stroke. Stroke was associated with a significant decline in function and an
61 increase in the likelihood of nursing home move, but stroke did not accelerate subsequent
62 disability accrual. Because of the high background rate of functional loss, stroke was not the
63 dominant determinant of population-level disability in older adults with AF.

64

65 **Introduction**

66 Atrial fibrillation (AF) is a significant health burden for older adults, affecting 1 in 25 of those over
67 age 60 and 1 in 10 over age 80.¹ Stroke is the most dreaded consequence of AF for older
68 adults, who often equate stroke with abrupt and persistent loss of independence.

69
70 While prior studies have clearly demonstrated that AF-related strokes result in increased short-
71 term disability, long-term functional outcomes for AF patients generally, and specifically before
72 and after stroke, remain uncharted.² While many strokes result in sudden and life-altering
73 disability, disability can also result from an accumulation of impairments independent of stroke.
74 Particularly in older adults, AF frequently coexists with other medical conditions that increase
75 the risk of disability.^{3,4} Also, while often overlooked, geriatric syndromes, such as falls and
76 cognitive impairment, are also important contributors to loss of independence in older AF
77 patients.^{5,6} In large and nationally representative cohorts of older adults with AF, frailty, cognitive
78 impairment, and functional impairments are common.^{7,8} In the absence of longitudinal data in
79 older adults with AF, the contribution of stroke and factors besides stroke to long-term
80 disablement remains unclear.

81
82 Stroke is perceived as a dominant pathway to disability in patients with AF, yet information
83 assessing its actual population health burden is limited. Compared to the prevalence of other
84 risk factors for disability, stroke remains an uncommon occurrence even among AF patients.
85 Thus, many older adults with AF may be predisposed to disablement even in the absence of
86 stroke, but this has not been previously quantified.

87
88 Understanding the longitudinal course of independence of older patients with AF, and whether
89 and to what degree stroke affects their long-term trajectory, is vital to inform treatment decision-
90 making, advance care planning, and public health interventions. To address these gaps, we

91 used a nationally representative cohort of older adults with incident AF to determine long-term
92 functional outcomes and the relative contribution of strokes.

93

94 **Methods**

95 *Study design and participants*

96 We performed a longitudinal, observational study to examine the association between incident
97 stroke and functional status in a cohort of older adults with AF. We used data from 1992-2014
98 from the Health and Retirement Study (HRS), a longitudinal, nationally representative survey of
99 more than 37,500 Americans age 50 and older, which amounts to 350,000 person-years of
100 observation.⁹ Subjects are interviewed every two years by phone, in person or via internet
101 surveys. The goal of the HRS is to measure changes in health, wealth, social structure, and
102 function as participants retire, with questions covering four aging-related topics: economic
103 security, mental and physical health and function, work and retirement, and social connections.
104 Proxy interviewees, typically family members, are used for those who cannot participate
105 because of physical or cognitive impairment. The HRS is linked to Medicare insurance claims
106 for participants who consent.¹⁰ The HRS sampling design yields a nationally representative
107 sample of community-dwelling adults and nursing home residents in the US.¹¹

108

109 We identified a cohort of HRS subjects aged 65 and older with Medicare claims linkage and
110 continuous Medicare Part A and B enrollment (cohort flow diagram **Appendix 1**). We included
111 participants if their claims had one inpatient or two outpatient claims for AF in the first or second
112 position (427.31 from the *International Classification of Diseases Ninth revision, Clinical
113 Modification*). Cases were defined as incident AF if they had 12 months of continuous
114 enrollment in Medicare Part A and B with no prior AF claims diagnosis.¹² To ensure accurate
115 information about participants' baseline characteristics, we excluded those whose first interview
116 occurred more than 2.5 years before their AF diagnosis; a timeframe of 2.5 years was selected

117 because of the variable biennial timing between HRS interviews.¹³ To obtain longitudinal
118 outcome and exposure information, we excluded participants who had no interviews after a
119 diagnosis of AF. Participants were censored at the time of disenrollment from Medicare part A
120 or B, HRS drop out, or death, whichever came first.

121

122 *Measures: Demographics and comorbidities*

123 We used HRS interview data to characterize participants' age, gender, education level, race,
124 ethnicity, education, marital status, and whether they lived alone. We report information on
125 comorbid conditions that affect stroke risk, including congestive heart failure, hypertension, prior
126 stroke, diabetes mellitus, prior myocardial infarction or angina, or cancer (excluding skin
127 cancer). We characterized patients as having a specific clinical comorbidity if (1) they report a
128 physician had ever told them they had a specific condition or (2) they met Medicare claims
129 criteria (definitions found in **Appendix 2**). Prior studies have examined the validity of self-
130 reported cardiovascular comorbidities, such as those used in the CHA₂DS₂-VASc score, finding
131 self-reported diagnoses to reflect medical charts and population-level estimates accurately.^{14–16}
132 Clinical characteristics were used to compute a CHA₂DS₂-VASc (Congestive heart failure,
133 Hypertension, Age, Diabetes mellitus, Stroke, Vascular disease, and Sex) score to estimate the
134 risk of ischemic stroke.¹⁷ We report participants' baseline demographic and comorbidity
135 information from the most recent interview before their AF diagnosis.

136

137 *Measures: Stroke*

138 We used a claims-based definition of ischemic (ICD-9 codes: 434.x and 436.x; ICD10: I63.x)
139 and hemorrhagic stroke (ICD9: 430.x and 431.x; ICD10: I61.x).¹⁸ To classify incident stroke
140 events, we identified subjects with an inpatient admission with a primary diagnosis code for
141 ischemic or hemorrhagic stroke. We examined the first stroke after AF diagnosis for each
142 participant in the analysis.

143 *Outcomes: Function*

144 We measured the effect of strokes on three functional outcomes: activities of daily living (ADL)
145 impairment, instrumental activities of daily living (IADL) impairment, and community dwelling.
146 We defined ADL dependence as a respondent stating that they required help with any of 6
147 ADLs (walking, dressing, bathing, eating, transferring to or from bed, and toileting). We defined
148 IADL dependence as a respondent stating that they required assistance with any of 5 IADLs
149 (preparing a hot meal, shopping for groceries, making telephone calls, taking medicines, and
150 managing money). We defined nursing home move as spending ≥ 90 nights in a nursing home
151 since the last interview. We defined the outcome of community-dwelling as no nursing home
152 move since the last interview. All three functional outcomes were measured at each interview.

153

154 *Analysis*

155 We measured the prevalence of cohort demographics and comorbidities at the time of AF
156 diagnosis. To determine the association between stroke and each functional outcome, we fit
157 separate random-effects logistic regression models with repeated measures. We modeled the
158 effect of stroke on function by including an interaction term between stroke and time since AF
159 diagnosis (modeling equation in **Appendix 3**). In each model, we adjusted for covariates,
160 defined a priori, that contribute to stroke and disability: age, sex, congestive heart failure,
161 hypertension, prior stroke, diabetes mellitus, prior myocardial infarction or angina, or history of
162 cancer (excluding skin cancer). We determined the log-odds for each outcome: ADL
163 dependence, IADL dependence, and nursing home residence. To visually illustrate the effect of
164 stroke on the probability of ADL independence, IADL independence, and nursing home
165 residence, we present the predicted population rates and the average marginal effects.¹⁹ We did
166 not use significance testing to determine which confounders to include in the regression models,
167 consistent with epidemiologic best practices.¹⁹ If, during an otherwise completed interview, ADL,
168 IADL, nursing home status were not obtained, the participant was not included in the analysis

169 for that outcome in that time period (<4% of interviews). A substantial proportion of missing
170 interviews were exit interviews with next-of-kin (1.5% of all interviews). When an exit interview
171 was completed, next-of-kin reported ADL and IADL dependence >90% of the time. As such,
172 when exit interviews were missing, we imputed ADL and IADL status as dependent.

173
174 To estimate the contribution of strokes to the overall population burden of functional impairment
175 in patients with AF, we used the method of recycled predictions.^{20,21} First, using the regression
176 model results (**Appendix 4**) and the observed stroke rate, we estimated the burden of
177 dependence for the population that had a stroke and the population that did not have a stroke
178 projected over 7.4 (measured in disability-years). We chose 7.4 years because it was the 75th
179 percentile of follow-up time. Next, we used the same parameters to estimate the disability-years
180 for the same population assuming no strokes had occurred. The difference between the two
181 measures of disability-years represents the disability-years attributable to stroke (detailed
182 methods and visual description presented in **Appendix 5**).

183
184 We performed all analyses using SAS 9.4 (Cary, NC) and STATA (Version 16.1, College
185 Station, TX). We report all results with 95% confidence intervals. STROBE statement checklist
186 can be found in **Appendix 6**.

187

188 **Results**

189 *Cohort characteristics*

190 We included 3,530 participants in our analysis with an average of 4.9 years of follow-up time,
191 amounting to 17,396 person-years of observation. At the time of AF diagnosis, the median age
192 was 79 years, 53% were women, 85% identified as white, 9.0% as Black, and 10.0% were
193 proxy interviews (**Table**). The most common comorbid condition among participants was
194 hypertension (79%), followed by prior myocardial infarction or angina (58%), congestive heart

195 failure (36%), diabetes (31%), prior stroke (23%), and cancer (22%). The median CHA₂DS₂-
196 VASc score in the cohort was 5 (IQR 4, 7). During the follow-up period after AF diagnosis, 262
197 participants, or 7.4%, had a stroke (1.5 strokes per 100 person-years). The median time from
198 AF diagnosis to stroke was 2.8 years (IQR 0.8, 6.0).

199

200 *Longitudinal functional outcomes*

201 Figure 1 graphically represents three key findings for each of the three functional outcomes—
202 the baseline rate of lost function independent of stroke, the immediate loss of function following
203 stroke, and change in the baseline rate of lost function following stroke. We present the full
204 model results, including unadjusted results in **Appendix 4**.

205

206 Independent of stroke and accounting for comorbidities, the absolute likelihood of ADL
207 independence decreased by 4.4% per year (average marginal effect [AME], 95% CI 4.0 to 4.8%
208 per year) (**Figure 1A**). Assuming a stroke at 2.8 years, the median time to stroke in this cohort,
209 stroke was associated with a decrease in the predicted likelihood of independence from 58%
210 (pre-stroke) to 27% (post-stroke) (AME -32%, 95% CI -25 to -39%). Stroke, however, was not
211 associated with a change in the baseline rate of decline in ADL independence; that is, the
212 relative rate of ADL decline post-stroke did not differ when compared to those without stroke.

213

214 Similar to ADL independence, independent of stroke and accounting for comorbidities, the
215 absolute likelihood of IADL independence decreased by 3.9% per year (AME, 95% CI 3.5 to
216 4.3% per year) (**Figure 1B**). Assuming a stroke at 2.8 years, stroke was associated with a
217 decrease in the predicted likelihood of IADL independence from 52% to 26% (AME -27%, 95%
218 CI -20 to -33%). Stroke was not associated with a change in the baseline annual rate of decline
219 in IADL independence.

220

221 Finally, for community-dwelling, independent of stroke and accounting for comorbidities, the
222 absolute likelihood of community-dwelling decreased by 1.2% per year (AME, 95% CI 1.0 to
223 1.4% per year) (Figure 1C). Assuming a stroke at 2.8 years, stroke was associated with a
224 decrease in the predicted likelihood of community-dwelling from 94% to 85% (AME -8.6%; 95%
225 CI -3.7 to -13.5%). Stroke was not associated with a change in the baseline annual rate of
226 decline in community-dwelling.

227

228 *Population-level outcomes*

229 Projected over 7.4 years, stroke accounted for a modest proportion of dependent-years among
230 older adults with AF (**Figure 2**). Stroke accounted for 1.7% (95% CI 1.3 to 2.1%) of the
231 population burden of ADL disability (for 100 person-years, 46.4 dependent-years given
232 observed stroke rate vs. 45.6 disability-years assuming no strokes; attributable burden 0.8
233 disability-years/100 person-years or 1.7%). For IADL impairment, 1.2% (95% CI 0.9 to 1.6%) of
234 the population burden of IADL disability could be attributed to stroke (for 100 person years, 51.8
235 dependent-years given observed stroke rate vs. 51.1 dependent-years assuming no strokes;
236 attributable burden 0.6 dependent-years/100 person-years or 1.2%). For loss of community-
237 dwelling, 7.3% (95% CI 4.0 to 10.5%) of the population burden of nursing home years could be
238 attributed to stroke (for 100 person-years, 7.7 nursing home-years given observed stroke rate
239 vs. 7.2 nursing home-years assuming no strokes; attributable burden 0.6 nursing home-
240 years/100 person-years or 7.3%).

241

242 **Discussion**

243 In this nationally representative cohort, we determined that older adults with AF experience a
244 significant loss of function over time. First, following AF diagnosis and independent of stroke, we
245 found a high rate of loss of function and nursing home moves—annual increases of 4.4% in
246 ADL dependence, 3.9% increase in IADL dependence, and 1.2% annual increase in nursing

247 home residence. Second, stroke was associated with an immediate and substantial decline in
248 function and an increase in the likelihood of nursing home move. In the years following a stroke,
249 stroke survivors and those who did not experience a stroke accrued disability at similar rates;
250 that is, the loss of independence did not accelerate following stroke.

251
252 Contrary to prevailing wisdom, we found stroke was not the dominant determinant of disability in
253 older adults with AF on a population level. While a stroke results in striking loss of function for
254 the 1 in 13 that suffer a stroke, we found the high background rate of function loss independent
255 of stroke is the predominant pathway for population disability. In this AF cohort, projected over
256 seven years, stroke accounted for 1.7% of ADL disability-years, 1.2% of IADL disability-years,
257 and 7.3% of total time in nursing homes. Although AF-related stroke causes substantial, sudden
258 loss of function for individuals and represents a substantial public health burden, most AF
259 patients become disabled through other means.

260
261 These findings add to limited literature describing long-term functional outcomes among older
262 adults with AF. Two recent studies have compared the risk of disability among AF patients
263 versus those without AF. Marzona et al. showed that incident AF was associated with increased
264 loss of ADL independence, as well as rates of admission to long-term care facilities, compared
265 to those without AF.²² These associations were independent of stroke. However, because this
266 study drew from patients enrolled in randomized controlled trials, with mean age a decade
267 younger than in the current study, its results may be less generalizable to the older AF
268 population. In a cohort of adults over age 65, Wallace et al. demonstrated that, even after
269 adjusting for incident stroke or heart failure, incident AF was associated with 50% shorter
270 disability-free survival and 24% higher risk of ADL disability than those without AF.²³

271
272 The results of this study make clear that older adults with AF acquire disabilities through

273 multiple mechanisms. Thus, mitigating disability may require distinct interventions. To
274 ameliorate stroke-related disability, optimizing anticoagulant use and left atrial closure devices
275 continues to be a primary concern.^{24,25} While this study demonstrates the importance of stroke-
276 independent disability, the causes of stroke-independent disability are not well defined. Some
277 have postulated a direct link between the dysrhythmia itself and function independent of stroke.
278 For example, alterations in cardiac structure resulting from AF impair cardiac output could
279 reduce patients' capacity for both cognitive and physical activities.²⁶ In addition to clinically
280 diagnosed stroke, AF has also been associated with subclinical ischemic events and resultant
281 disability.^{27,28} In this scenario, strategies could target preventing the development of atrial
282 fibrillation altogether or preventing its cardiac remodeling effects. Rather than a causal
283 connection between AF and disability, AF may instead be a marker for multimorbidity, frailty,
284 and other geriatric syndromes that predispose to impairment. In this model, novel geriatric care
285 models that address functional impairment using multifaceted interventions may hold promise.²⁹
286 In either circumstance, when counseling patients and families regarding a diagnosis of AF, our
287 results should prompt a discussion of the risk of functional dependence in the years following
288 diagnosis of AF that is only partially mitigated by stroke prevention.

289
290 Our study has several limitations that should be considered when interpreting the results. We
291 relied on self-report for functional status measures, which are subject to recall bias, as subjects
292 may be reluctant to acknowledge these limitations or may not recall them due to cognitive
293 deficits. We excluded participants who lacked follow-up data, which could have preferentially
294 excluded those with more significant functional impairments who had difficulty completing
295 follow-up interviews. However, both limitations would likely result in underestimating the true
296 burden of disability and bias our results toward the null. The HRS assesses functional status
297 every two years, but functional deficits can develop rapidly, as such important changes could be
298 missed with this interval. Also, several studies have shown that older adults can have periods of

299 decline and recovery, but our data did not allow for this degree of granularity.³⁰ Nevertheless,
300 although older adults often recover from initial disability, an episode of disability is a strong
301 predictor of chronic impairment, so the overarching trajectory of function illustrated in our cohort
302 remains informative.³¹ Participants with the most severe or deadly strokes may be differentially
303 censored. To mitigate this bias, we assumed that all participants who died and were missing
304 outcome data were disabled before death. In a sensitivity analysis, we examined if there was a
305 differential loss to follow-up following a stroke. We did not find a significant association between
306 stroke and differential loss to follow-up (**Appendix 7**); this reduces the likelihood but does not
307 eliminate this potential bias. Finally, Medicare Part D prescription data are only available from
308 2006 onward. Stroke severity and short-term disability are both reduced by receipt of
309 anticoagulant or antithrombotic medications, so this represents an important unmeasured
310 confounder in our results that should be evaluated in future studies.³²

311
312 In conclusion, we found that long-term functional decline was common in older adults with AF
313 and mostly occurred in the absence of stroke. After seven years, one-third of AF patients had
314 ADL disability, one-half IADL disability, and one-tenth lived in a nursing home. Considering the
315 public health implications of AF in older adults, our results demonstrate that although stroke
316 represents a significant cause of functional decline, most disability results from other causes.
317 These results challenge the traditional thinking that the long-term function of AF patients
318 depends principally on stroke prevention. Taken together, our findings emphasize the need to
319 supplement stroke prevention along with multifaceted interventions to prevent dependence.

320 **Acknowledgments**

321

322 **Contributors:** ALP, SYJ, WJB, and SJS, were responsible for the study concept and design.
323 ALP, MAS, AKS, and SJS obtained funding and supervised the study. All authors were involved
324 in the acquisition, analysis, or interpretation of the data. SJY performed the statistical analyses.
325 ALP and SJS drafted the manuscript, and all authors critically revised it for important intellectual
326 content. The corresponding author attests that all listed authors meet authorship criteria and
327 that no others meeting the criteria have been omitted. ALP, SYJ, and SJS had full access to all
328 the data in the study and are the guarantors.

329

330 **Funding:** This study was supported by the National Center for Advancing Translational
331 Sciences (KL2TR001870), the National Institute on Aging (P30AG044281, K24AG068312 ,
332 K24AG049057 & T32-AG000212), and the National Heart Lung and Blood Institute
333 (K24HL141354).

334

335 **Sponsor's Role:** The funders had no role in study design, data collection and analysis, decision
336 to publish, or preparation of the manuscript.

337

338 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
339 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author). MCF
340 reports grants from NIH/NHLBI, during the conduct of the study. ALP, MAS, AKS report grants
341 from NIH/NIA, during the conduct of the study. SJS reports grants from NIH/NCATS, during the
342 conduct of the study. No financial relationships with any organizations that might have an
343 interest in the submitted work in the previous three years; no other relationships or activities that
344 could appear to have influenced the submitted work.

345

346 **Ethical approval:** The Human Research Protection Program Institutional Review Board at the
347 University of California, San Francisco, approved this study (IRB# 16-19185).

348

349 **Data sharing:** Researchers can apply to use the Health and Retirement Study
350 (hrs.isr.umich.edu/) for access to the data use in this study. Code used to generate the cohort
351 and perform the analyses can be found on github (<https://github.com/sachinjshah>).

352

353 References

- 354 1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults:
355 National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation
356 and Risk Factors In Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001;285(18):2370-2375.
357 doi:10.1001/jama.285.18.2370
- 358 2. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham
359 Study. *Stroke*. 1996;27(10):1760-1764. doi:10.1161/01.str.27.10.1760
- 360 3. Parks AL, Fang MC. Anticoagulation in Older Adults with Multimorbidity. *Clin Geriatr Med*.
361 2016;32(2):331-346. doi:10.1016/j.cger.2016.01.003
- 362 4. Stuck AE, Walthert JM, Nikolaus T, Büla CJ, Hohmann C, Beck JC. Risk factors for
363 functional status decline in community-living elderly people: a systematic literature review.
364 *Soc Sci Med*. 1999;48(4):445-469. doi:10.1016/S0277-9536(98)00370-0
- 365 5. Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric Syndromes: Clinical, Research,
366 and Policy Implications of a Core Geriatric Concept. *J Am Geriatr Soc*. 2007;55(5):780-791.
367 doi:10.1111/j.1532-5415.2007.01156.x
- 368 6. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the Concepts of
369 Disability, Frailty, and Comorbidity: Implications for Improved Targeting and Care. *J*
370 *Gerontol Ser A*. 2004;59(3):M255-M263. doi:10.1093/gerona/59.3.M255
- 371 7. Mailhot T, McManus DD, Waring ME, et al. Frailty, Cognitive Impairment, and
372 Anticoagulation Among Older Adults with Nonvalvular Atrial Fibrillation. *J Am Geriatr Soc*.
373 n/a(n/a). doi:10.1111/jgs.16756
- 374 8. Shah SJ, Fang MC, Jeon SY, Gregorich SE, Covinsky KE. Geriatric Syndromes and Atrial
375 Fibrillation: Prevalence and Association with Anticoagulant Use in a National Cohort of
376 Older Americans. *J Am Geriatr Soc*. n/a(n/a). doi:10.1111/jgs.16822
- 377 9. Juster FT, Suzman R. An Overview of the Health and Retirement Study. *J Hum Resour*.
378 1995;30:S7-S56. doi:10.2307/146277
- 379 10. Fisher GG, Ryan LH. Overview of the Health and Retirement Study and Introduction to the
380 Special Issue. *Work Aging Retire*. 2018;4(1):1-9. doi:10.1093/workar/wax032
- 381 11. Sonnega A, Faul JD, Ofstedal MB, Langa KM, Phillips JWR, Weir DR. Cohort Profile: the
382 Health and Retirement Study (HRS). *Int J Epidemiol*. 2014;43(2):576-585.
383 doi:10.1093/ije/dyu067
- 384 12. Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR. Identifying Hypertension-
385 Related Comorbidities From Administrative Data: What's the Optimal Approach? *Am J Med*
386 *Qual*. 2004;19(5):201-206. doi:10.1177/106286060401900504
- 387 13. Tang VL, Sudore R, Cenzer IS, et al. Rates of Recovery to Pre-Fracture Function in Older
388 Persons with Hip Fracture: an Observational Study. *J Gen Intern Med*. 2017;32(2):153-158.
389 doi:10.1007/s11606-016-3848-2

- 390 14. Bush TL, Miller SR, Golden AL, Hale WE. Self-report and medical record report agreement
391 of selected medical conditions in the elderly. *Am J Public Health*. 1989;79(11):1554-1556.
392 doi:10.2105/AJPH.79.11.1554
- 393 15. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-
394 report questionnaires and medical record data was substantial for diabetes, hypertension,
395 myocardial infarction and stroke but not for heart failure. *J Clin Epidemiol*.
396 2004;57(10):1096-1103. doi:10.1016/j.jclinepi.2004.04.005
- 397 16. Glymour MM, Avendano M. Can self-reported strokes be used to study stroke incidence and
398 risk factors?: evidence from the health and retirement study. *Stroke*. 2009;40(3):873-879.
399 doi:10.1161/STROKEAHA.108.529479
- 400 17. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical Risk Stratification
401 for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-
402 Based Approach: The Euro Heart Survey on Atrial Fibrillation. *CHEST*. 2010;137(2):263-
403 272. doi:10.1378/chest.09-1584
- 404 18. Kokotailo Rae A., Hill Michael D. Coding of Stroke and Stroke Risk Factors Using
405 International Classification of Diseases, Revisions 9 and 10. *Stroke*. 2005;36(8):1776-1781.
406 doi:10.1161/01.STR.0000174293.17959.a1
- 407 19. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable
408 analysis - PubMed. Accessed August 26, 2020. [https://pubmed.ncbi.nlm.nih-](https://pubmed.ncbi.nlm.nih.gov/ucsf.idm.oclc.org/8699212/)
409 [gov.ucsfc.idm.oclc.org/8699212/](https://pubmed.ncbi.nlm.nih.gov/ucsf.idm.oclc.org/8699212/)
- 410 20. Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating model-adjusted risks, risk
411 differences, and risk ratios from complex survey data. *Am J Epidemiol*. 2010;171(5):618-
412 623. doi:10.1093/aje/kwp440
- 413 21. Graubard BI, Korn EL. Predictive margins with survey data. *Biometrics*. 1999;55(2):652-659.
414 doi:10.1111/j.0006-341x.1999.00652.x
- 415 22. Marzona I, O'Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in
416 patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. *CMAJ*
417 *Can Med Assoc J*. 2012;184(6):E329-E336. doi:10.1503/cmaj.111173
- 418 23. Wallace ER, Siscovick DS, Sitlani CM, et al. Incident Atrial Fibrillation and Disability-Free
419 Survival in the Cardiovascular Health Study. *J Am Geriatr Soc*. 2016;64(4):838-843.
420 doi:10.1111/jgs.14037
- 421 24. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure:
422 From the PREVAIL and PROTECT AF Trials. *J Am Coll Cardiol*. 2017;70(24):2964-2975.
423 doi:10.1016/j.jacc.2017.10.021
- 424 25. Okumura K, Akao M, Yoshida T, et al. Low-Dose Edoxaban in Very Elderly Patients with
425 Atrial Fibrillation. *N Engl J Med*. 2020;0(0):null. doi:10.1056/NEJMoa2012883
- 426 26. Groenveld HF, Crijns HJGM, Van den Berg MP, et al. The Effect of Rate Control on Quality
427 of Life in Patients With Permanent Atrial Fibrillation: Data From the RACE II (Rate Control

- 428 Efficacy in Permanent Atrial Fibrillation II) Study. *J Am Coll Cardiol*. 2011;58(17):1795-1803.
429 doi:10.1016/j.jacc.2011.06.055
- 430 27. Rosano C, Kuller LH, Chung H, Arnold AM, Longstreth WT, Newman AB. Subclinical brain
431 magnetic resonance imaging abnormalities predict physical functional decline in high-
432 functioning older adults. *J Am Geriatr Soc*. 2005;53(4):649-654. doi:10.1111/j.1532-
433 5415.2005.53214.x
- 434 28. Petersen P, Madsen EB, Brun B, Pedersen F, Gyldensted C, Boysen G. Silent cerebral
435 infarction in chronic atrial fibrillation. *Stroke*. 1987;18(6):1098-1100.
436 doi:10.1161/01.STR.18.6.1098
- 437 29. Szanton SL, Leff B, Wolff JL, Roberts L, Gitlin LN. Home-Based Care Program Reduces
438 Disability And Promotes Aging In Place. *Health Aff (Millwood)*. 2016;35(9):1558-1563.
439 doi:10.1377/hlthaff.2016.0140
- 440 30. Hardy SE, Gill TM. Recovery From Disability Among Community-Dwelling Older Persons.
441 *JAMA*. 2004;291(13):1596-1602. doi:10.1001/jama.291.13.1596
- 442 31. Gill TM, Kurland BF. Prognostic Effect of Prior Disability Episodes among Nondisabled
443 Community-living Older Persons. *Am J Epidemiol*. 2003;158(11):1090-1096.
444 doi:10.1093/aje/kwg237
- 445 32. Jung YH, Kim YD, Kim J, et al. Initial Stroke Severity in Patients With Atrial Fibrillation
446 According to Antithrombotic Therapy Before Ischemic Stroke. *Stroke*. 2020;51(9):2733-
447 2741. doi:10.1161/STROKEAHA.120.030138

448

449 Table: Baseline characteristics of the cohort of older adults with atrial fibrillation

	Prevalence (95% CI) n=3530
Sociodemographics	
Age, median (IQR)	79 (72, 85)
Women	53% (52, 55)
Married or Partnered	53% (52, 55)
Lives alone	31% (30, 33)
Greater than high school education	68% (67, 70)
Race	
White	85% (84, 86)
Black	9% (8, 10)
Other	2% (1, 2)
Hispanic ethnicity	5% (4, 5)
Proxy interview	10% (9, 12)
Medical comorbidities	
Congestive heart failure (%)	36% (34, 38)
Hypertension (%)	79% (77, 80)
Diabetes mellitus (%)	31% (30, 33)
Prior stroke (%)	23% (22, 25)
History of vascular disease (%)	58% (56, 59)
Cancer (%)	22% (20,23)
CHA ₂ DS ₂ -VASc, median (IQR)*	5 (4, 7)
1	2% (1,2)
2	5%(5,6)
3	11% (10,12)
4	18% (16,19)
5	21% (19,22)
6	18% (17,20)
7	13% (12,14)
8	9%(8,10)
9	3% (3,4)
Function at baseline	
ADL disability (%)	16% (15, 17)
IADL disability (%)	22% (20, 23)
Nursing home residence (%)	3% (2, 3)

450


451 Caption

452 IQR – interquartile range; CHA₂DS₂-VASc score - congestive heart
453 failure/hypertension/age/diabetes/stroke/vascular disease

454 * none with CHA₂DS₂-VASc score of 0


455 Characteristics from baseline interview prior to AF diagnosis.

456 Figure 1: Longitudinal likelihood of ADL independence, IADL independence, and community
457 dwelling and association with stroke



458
459
460 **Caption**
461 ADL – activity of daily living; IADL – instrumental activity of daily living
462 The slope represents the average marginal effect of a one-year change on independence, adjusting for
463 demographics and comorbidities. The blue line represents the predicted likelihood of the outcome without
464 stroke and the red line represents the predicted likelihood of the outcome following stroke at 2.8 years
465 (the median time to stroke in the cohort). For the population who goes on to have a stroke, the blue line
466 from 0 to 2.8 years represents the pre-stroke trajectory and the red line describes the post-stroke
467 trajectory. Functional trajectory is displayed through 7.4 years, the 75th percentile of follow up time. The
468 analysis is based on 3530 participants; we excluded 26 person waves (0.3%) with missing ADL outcome
469 data, 213 person-waves (2.1%) with missing IADL outcome data, and 368 person-waves (3.5%) with
470 missing nursing home outcome data.

471 Figure 2: Contribution of strokes to population ADL independence, IADL independence, and
472 community-dwelling over 100 person-years
473



474
475

476 Caption:
477 ADL – activity of daily living; IADL – instrumental activity of daily living
478
479 Each icon represents 0.5 person-years. Each panel contains 200 icons summing to 100 person-years.
480 Values are all rounded to the nearest 0.5. Exact values are presented in the text of the results.
481
482 To estimate the population burden of dependence attributable to strokes, we used the regression model
483 results to calculate the likelihood of independence for each person based on their comorbidities and
484 accounting for their survey sampling weight over seven years. Next, we used the same parameters to
485 estimate the dependent-years for the same population assuming no strokes had occurred. The difference
486 between the two measures of dependent-years represents the dependent-years attributable to stroke
487 over 100 person-years (red icons, each representing 0.5 person-years). The blue icons represent
488 independent 0.5 person-years. The yellow icons represent 0.5 dependent-years, not attributable to stroke.

489 **Appendix to “Long-term individual and population functional outcomes in older adults with atrial**
490 **fibrillation”**

491
492 Anna L. Parks, MD (1), Sun Y. Jeon, MS PhD (2), Michael A. Steinman, MD (2), Alexander K. Smith, MD,
493 MPH, MAS (2), Margaret C. Fang, MD, MPH (3), Sachin J. Shah, MD, MPH (3)

494
495 (1) Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA

496 (2) Division of Geriatrics, University of California, San Francisco, San Francisco, CA

497 (3) Division of Hospital Medicine, University of California, San Francisco, San Francisco, CA

498

499

500 **Contents**

501	Appendix 1: Cohort flow diagram.....	2
502	Appendix 2: Medicare claims comorbidity definitions	3
503	Appendix 3: Modeling equation.....	4
504	Appendix 4: Manuscript Figure 1 results as table	5
505	Appendix 5: Description of the method of recycled predictions to determine the contribution of	
506	strokes to population-level burden of disability.....	6
507	Appendix 6: STROBE statement checklist	7
508	Appendix 7: Rates of censoring by stroke status	9

509


510

511

512 **Appendix 1: Cohort flow diagram**

513

514



515 **Appendix 2: Medicare claims comorbidity definitions**

516

Condition	Criteria and reference period	Valid ICD-9 Codes
Congestive heart failure	≥1 inpatient, HOP or Carrier claim in the last 2 years	398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.9, 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.9 (in any position)
Hypertension	≥ 1 inpatient, SNF, HHA OR 2 HOP or Carrier claim in the last 1 year	362.11, 401.0, 401.1, 401.9, 402.00, 402.01, 402.10, 402.11, 402.90, 402.91, 403.00, 403.01, 403.10, 403.11, 403.90, 403.91, 404.00, 404.01, 404.02, 404.03, 404.10, 404.11, 404.12, 404.13, 404.90, 404.91, 404.92, 404.93, 405.01, 405.09, 405.11, 405.19, 405.91, 405.99, 437.2 (in any position)
Diabetes	≥1 inpatient, SNF or HHA OR ≥2 HOP or Carrier claims in the last 2 years	249.00, 249.01, 249.10, 249.11, 249.20, 249.21, 249.30, 249.31, 249.40, 249.41, 249.50, 249.51, 249.60, 249.61, 249.70, 249.71, 249.80, 249.81, 249.90, 249.91, 250.00, 250.01, 250.02, 250.03, 250.10, 250.11, 250.12, 250.13, 250.20, 250.21, 250.22, 250.23, 250.30, 250.31, 250.32, 250.33, 250.40, 250.41, 250.42, 250.43, 250.50, 250.51, 250.52, 250.53, 250.60, 250.61, 250.62, 250.63, 250.70, 250.71, 250.72, 250.73, 250.80, 250.81, 250.82, 250.83, 250.90, 250.91, 250.92, 250.93, 357.2, 362.01, 362.02, 362.03, 362.04, 362.05, 362.06, 366.41 (in any position)
Prior stroke	≥1 inpatient OR 2 HOP or Carrier claims in the last 1 year	DX 430, 431, 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.00, 434.01, 434.10, 434.11, 434.90, 434.91, 435.0, 435.1, 435.3, 435.8, 435.9, 436, 997.02 (any DX on the claim); EXCLUSION: If any of the qualifying claims have: 800 ≤ DX Code ≤ 804.9, 850 ≤ DX Code ≤ 854.1 in any DX position OR DX V57xx as the principal DX Code, then EXCLUDE.
Vascular disease: Acute myocardial infarction Ischemic heart disease	Acute myocardial infarction: ≥1 inpatient claim in the last 1 year Ischemic heart disease: ≥1 inpatient, SNF, HHA, HOP or Carrier claim in last 2 years	Acute myocardial infarction: DX 410.01, 410.11, 410.21, 410.31, 410.41, 410.51, 410.61, 410.71, 410.81, 410.91 (ONLY first or second DX on the claim) Ischemic heart disease: DX 410.00, 410.01, 410.02, 410.10, 410.11, 410.12, 410.20, 410.21, 410.22, 410.30, 410.31, 410.32, 410.40, 410.41, 410.42, 410.50, 410.51, 410.52, 410.60, 410.61, 410.62, 410.70, 410.71, 410.72, 410.80, 410.81, 410.82, 410.90, 410.91, 410.92, 411.0, 411.1, 411.81, 411.89, 412, 413.0, 413.1, 413.9, 414.00, 414.01, 414.02, 414.03, 414.04, 414.05, 414.06, 414.07, 414.12, 414.2, 414.3, 414.4, 414.8, 414.9 (any DX on the claim)
Cancer	≥1 inpatient, SNF OR 2 HOP or Carrier claims in last 1 year	DX 153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7, 153.8, 153.9, 154.0, 154.1, 230.3, 230.4, V10.05, V10.06, DX 174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9, 175.0, 175.9, 233.0, V10.3, DX 162.2, 162.3, 162.4, 162.5, 162.8, 162.9, 231.2, V10.11, DX 185, 233.4, V10.46, DX C61, D07.5, Z85.46 (any DX on the claim)

517

518

519 **Appendix 3: Modeling equation**

520

521 We fit the following model random effects model using a binary distribution and logit link to estimate the
522 association of stroke and function (ADL, IADL, and independent living).

523

$$524 \text{logit}(E(Y_{it})) = \mu_t + \beta_1 T_t + \beta_2 S_{it} + \beta_3 T_t S_{it} + \beta x_{it} + \gamma z_i + \alpha_i$$

525

526 Where:

527 Y_{it} = disability at time t for individual i

528 T = time since AF diagnosis

529 S = an indicator representing incident stroke and all time periods following an incident stroke

530 x = time-varying covariates (congestive heart failure, hypertension, diabetes, vascular disease, cancer,
531 marital status, living alone, proxy respondent)


532 z = time-invariant covariates (age at AF diagnosis, sex, history of stroke before AF diagnosis, race,
533 ethnicity, educational attainment)

534 α_i = unobserved individual specific effect

535

536 From this model, we determined the baseline relative risk of the outcome β_1 , the immediate change
537 associated with stroke β_2 , and the change in baseline relative risk following stroke β_3 . These changes are
538 graphically depicted below.

539



540

541 **Appendix 4: Manuscript Figure 1 results as table**

542

543 Odds ratios and average marginal effects of stroke on ADL, IADL, nursing home residence adjusted for
544 stroke risk

545

Outcome	Parameter	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	AME (95% CI)
ADL independence	Pre-stroke rate of incident disability β_1	0.67 (0.64-0.69)	0.92 (0.89-0.95)	-4.4%/yr (-4.0 to -4.8%/yr)
	Immediate change in disability following stroke β_2	0.02 (0.01-0.05)	0.10 (0.05-0.21)	-31.9% (-25.1 to -38.7%)
	Change in rate of incident disability post-stroke, relative to pre-stroke rate β_3	1.12 (1.01-1.25)	1.02 (0.93-1.12)	--
IADL independence	Pre-stroke rate of incident disability β_1	0.74 (0.71-0.76)	0.95 (0.92-0.97)	-3.9% (-3.5 to -4.3%)
	Immediate change in disability following stroke β_2	0.04 (0.02-0.10)	0.16 (0.08-0.32)	-26.5% (-19.8 to -33.3%)
	Change in rate of incident disability post-stroke, relative to pre-stroke rate β_3	1.09 (0.99-1.20)	1.02 (0.94-1.10)	--
Continuous independent living	Pre-stroke rate of incident disability β_1	0.74 (0.71-0.78)	0.96 (0.92-1.00)	-1.2% (-1.0 to -1.4%)
	Immediate change in disability following stroke β_2	0.07 (0.03-0.18)	0.24 (0.11-0.52)	-8.6% (-3.7% to -13.5%)
	Change in rate of incident disability post-stroke, relative to pre-stroke rate β_3	1.06 (0.93-1.20)	1.00 (0.91-1.11)	--

546

547 Legend

548 OR – odds ratio, AME – average marginal effect

549 Unadjusted model does not include any time-varying or time invariant covariates. Adjusted model as noted
550 in Appendix 4.

551

552 AME represents the predicted absolute change based on the population’s comorbidities. AME for “change
553 in rate of incident disability post stroke relative to pre-stroke rate” not estimated when the 95% CI for
554 adjusted OR included 1.

555 **Appendix 5: Description of the method of recycled predictions to determine the contribution of**
556 **strokes to population-level burden of disability**

557

558 To estimate the contribution of strokes to the population disability burden, we determined the dependent-
559 years had there been no strokes in the cohort.

560

561 First, we used the parameter estimates from the regression model (Appendix 4) to predict the probability of
562 independence for each individual over 7.4 years given their specific covariates, if they had a stroke and
563 when it occurred, and survey sampling weight. We did not project beyond 7.4 years because less than 25%
564 of the cohort contributed more than 7.4 years of follow up time. For the 7.4% who had a stroke, this
565 corresponds to the area of A + B. For the 92.6% that did not have a stroke, this corresponds to the area of A
566 + B + C.


567

568 Next, among the 8.4% who had a stroke, we predicted the likelihood of independence assuming they did
569 not have a stroke Area of A + B + C.

570

571 The difference between these two measures summed over the population represents the dependent-years
572 attributable to stroke. We used this method to estimate the population burden for each of the three
573 functional outcomes (ADL independence, IADL independence, community dwelling).

574



575

576

577

578 **Appendix 6: STROBE statement checklist**

579

580 **STROBE Statement—Checklist of items that should be included in reports of *cohort studies***

	Item No	Recommendation	Reported on page
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1, 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	4-5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-7
Bias	9	Describe any efforts to address potential sources of bias	4-7, 11
Study size	10	Explain how the study size was arrived at	4-5, Appendix 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
		(c) Explain how missing data were addressed	6-7
		(d) If applicable, explain how loss to follow-up was addressed	6-7
		(e) Describe any sensitivity analyses	11
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Appendix 1
		(b) Give reasons for non-participation at each stage	4, 5, Appendix 1
		(c) Consider use of a flow diagram	Appendix 1

Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	Appendix 1
		(c) Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	Report numbers of outcome events or summary measures over time	8-9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-9, Appendix 4
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	8-10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11, Appendix 7
Discussion			
Key results	18	Summarise key results with reference to study objectives	9, 10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11, 12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	10-12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

581

582

583

584 **Appendix 7: Rates of censoring by stroke status**

585

Censored/year*	No stroke (N=3268)		Stroke (N=262)	
	N	%	N	%
0-1	735	22%	23	9%
1-2	348	11%	30	11%
2-3	353	11%	32	12%
3-4	276	8%	16	6%
4-5	285	9%	22	8%
5-6	220	7%	19	7%
6-7	190	6%	22	8%
7-8	156	5%	20	8%
8-9	127	4%	11	4%
9-10	128	4%	14	5%
10-11	94	3%	10	4%
11-12	74	2%	9	3%
12-13	73	2%	9	3%
13-14	62	2%	5	2%
14-15	43	1%	9	3%
15-16	39	1%	3	1%
16-17	25	1%	0	0%
17-18	17	1%	1	0%
18-19	11	0%	2	1%
19-20	11	0%	2	1%
>20	1	0%	3	1%
Total	3268	100%	262	100%

586

587 Caption

588 *Participants were censored at the time of Medicare disenrollment, HRS drop out, or death, whichever came first.

To address the possible bias that those with the most severe or deadly strokes would be more likely to be censored, we performed a sensitivity analysis assessing rates of censoring by year according to stroke status. As demonstrated above, there was no differential loss to follow-up by stroke status. Moreover, rates of censoring were similar between stroke versus non-stroke on a year-by-year basis.

589